Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 10/20 | 0.37 |
| ▸ | SLC6A2 | P23975 | 9/20 | 0.37 |
| ▸ | SLC6A3 | Q01959 | 8/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | MAOB | P27338 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20436757 | 0.91 | STING1 (0.38) | SLC6A4SLC6A2SLC6A3ALDH1A1KMT2A | |
| SCHEMBL13823807 | 0.91 | STING1 (0.38) | SLC6A4SLC6A2SLC6A3ALDH1A1KMT2A | |
| SCHEMBL10075506 | 0.91 | SLC6A4 (0.46) | SLC6A4SLC6A2SLC6A3CYP2D6 | |
| SCHEMBL10041962 | 0.91 | SLC6A4 (0.46) | SLC6A4SLC6A2SLC6A3CYP2D6 | |
| SCHEMBL10070677 | 0.81 | SMN1; SMN2 (0.40) | SLC6A4SLC6A2SLC6A3ALDH1A1KMT2A | |
| SCHEMBL20340496 | 0.71 | SLC6A2 (0.37) | SLC6A4SLC6A2SLC6A3KMT2AMEN1 | |
| SCHEMBL10050930 | 0.71 | SLC6A2 (0.37) | SLC6A4SLC6A2SLC6A3KMT2AMEN1 | |
| SCHEMBL10071233 | 0.71 | SLC6A2 (0.37) | SLC6A4SLC6A2SLC6A3KMT2AMEN1 | |
| SCHEMBL10071231 | 0.71 | KMT2A (0.36) | SLC6A4SLC6A2SLC6A3ALDH1A1KMT2A | |
| SCHEMBL20341083 | 0.71 | SLC6A2 (0.44) | SLC6A4SLC6A2SLC6A3KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120095106-A1 | PREPARATION OF CHIRAL AMIDES AND AMINES | SUNOVION PHARMACEUTICALS INC. (US) | 2012-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120095106-A1 | PREPARATION OF CHIRAL AMIDES AND AMINES | PNMT, ALKBH5, ALKBH2 | SLC6A4 827/4885SLC6A2 374/4885SLC6A3 1382/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.